ISDA

Entry Detail

PDB ID:

2WF0

Keywords:

Title:

Human BACE-1 in complex with 4-ethyl-N-((1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-8-(2-oxo-1-pyrrolidinyl)-6-quinolinecarboxamide

Biological Source:

Source Organism:

HOMO SAPIENS

Host Organism:

CRICETULUS GRISEUS

PDB Version:

Deposition Date:

2009-04-02

Release Date:

2009-05-19

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.60 Å

R-Value Free:

0.20

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:BETA-SECRETASE 1
Mutations:YES
Chain IDs:A
Chain Length:392
Number of Molecules:1
Biological Source:HOMO SAPIENS

UniProt ID:P56817 Pfam ID:PF00026 EC:3.4.23.46

Ligand Molecules

ZY0

Primary Citation

Second Generation of Bace-1 Inhibitors. Part 1: The Need for Improved Pharmacokinetics.

Charrier, N, Clarke, B, Cutler, L, Demont, E, Dingwall, C, Dunsdon, R, Hawkins, J, Howes, C, Hubbard, J, Hussain, I, Maile, G, Matico, R, Mosley, J, Naylor, A, O'Brien, A, Redshaw, S, Rowland, P, Soleil, V, Smith, K.J, Sweitzer, S, Theobald, P, Vesey, D, Walter, D.S, Wayne, G.Show

Bioorg.Med.Chem.Lett. 19 3664 ? (2009)

PMID: 19428244 DOI: 10.1016/J.BMCL.2009.03.165

Abstact

Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimer's disease. We have recently disclosed a series of transition-state mimetic BACE-1 inhibitors showing nanomolar potency in cell-based assays. Amongst them, GSK188909 (compound 2) had favorable pharmacokinetics and was the first orally bioavailable inhibitor reported to demonstrate brain amyloid lowering in an animal model. In this Letter, we describe the reasons that led us to favor a second generation of inhibitors for further in vivo studies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures